$FTLF
FITLIFE BRANDS, INC. Stock $ftlf

$ftlf Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924010119 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$16.55M	$13.30M	$52.70M
YoY Change	54.12%	147.65%	82.97%
Cost Of Revenue	$9.262M	$7.936M	$31.27M
YoY Change	46.32%	149.4%	86.46%
Gross Profit	$7.287M	$5.363M	$21.43M
YoY Change	65.31%	145.11%	78.1%
Gross Profit Margin	44.03%	40.33%	40.67%
Selling, General & Admin	$3.736M	$3.403M	$12.16M
YoY Change	59.39%	144.82%	94.05%
% of Gross Profit	51.27%	63.45%	56.74%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$36.00K	$30.00K	$94.00K
YoY Change	89.47%	76.47%	42.42%
% of Gross Profit	0.49%	0.56%	0.44%
Operating Expenses	$3.906M	$3.433M	$12.25M
YoY Change	4.58%	143.99%	93.51%
Operating Profit	$3.381M	$1.930M	$9.177M
YoY Change	402.38%	147.12%	60.97%
Interest Expense	$414.0K	-$125.0K	-$547.0K
YoY Change	322.45%	-301.61%	-552.07%
% of Operating Profit	12.24%	-6.48%	-5.96%
Other Income/Expense, Net	-$414.0K		-$547.0K
YoY Change	331.25%		-552.07%
Pretax Income	$2.967M	$1.697M	$7.003M
YoY Change	414.21%	112.13%	20.29%
Income Tax	$807.0K	$217.0K	$1.707M
% Of Pretax Income	27.2%	12.79%	24.38%
Net Earnings	$2.160M	$1.480M	$5.296M
YoY Change	1284.62%	212.9%	19.58%
Net Earnings / Revenue	13.05%	11.13%	10.05%
Basic Earnings Per Share	$0.47		$1.18
Diluted Earnings Per Share	$0.43	$0.30	$1.08
COMMON SHARES
Basic Shares Outstanding	4.598M	4.590M	4.490K
Diluted Shares Outstanding	5.030M		4.905K

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.540M	$1.139M	$1.139M
YoY Change	-68.16%	-91.42%	-91.42%
Cash & Equivalents	$3.290M	$1.898M
Short-Term Investments
Other Short-Term Assets	$1.201M	$1.398M	$1.398M
YoY Change	-49.9%	1105.17%	1105.17%
Inventory	$8.869M	$9.091M	$9.091M
Prepaid Expenses
Receivables	$2.269M	$2.046M	$2.046M
Other Receivables	$113.0K	$1.019M	$1.019M
Total Short-Term Assets	$14.99M	$14.69M	$14.69M
YoY Change	-29.32%	-36.68%	-36.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$121.0K	$258.0K	$258.0K
YoY Change	2.54%	460.87%	73.15%
Goodwill	$13.34M	$13.29M
YoY Change	23.67%	3613.41%
Intangibles	$26.33M	$26.31M
YoY Change	238.85%	17439.33%
Long-Term Investments
YoY Change
Other Assets	$612.0K	$792.0K	$792.0K
YoY Change	-61.65%	-57.12%	-57.12%
Total Long-Term Assets	$40.49M	$40.65M	$40.65M
YoY Change	97.97%	1523.52%	1523.52%
TOTAL ASSETS
Total Short-Term Assets	$14.99M	$14.69M	$14.69M
Total Long-Term Assets	$40.49M	$40.65M	$40.65M
Total Assets	$55.49M	$55.35M	$55.35M
YoY Change	33.17%	115.3%	115.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.978M	$3.261M	$3.261M
YoY Change	-18.5%	8.88%	8.88%
Accrued Expenses	$1.470M	$1.113M	$1.113M
YoY Change	-26.02%	62.48%	62.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.500M	$4.500M	$4.500M
YoY Change	80.0%
Total Short-Term Liabilities	$11.83M	$10.34M	$10.34M
YoY Change	18.89%	142.08%	142.08%
LONG-TERM LIABILITIES
Long-Term Debt	$11.89M	$15.51M	$15.51M
YoY Change	18.94%
Other Long-Term Liabilities	$34.00K	$51.00K	$51.00K
YoY Change	-68.52%	4.08%	4.08%
Total Long-Term Liabilities	$11.89M	$15.56M	$15.56M
YoY Change	18.94%	31655.1%	31655.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.83M	$10.34M	$10.34M
Total Long-Term Liabilities	$11.89M	$15.56M	$15.56M
Total Liabilities	$26.11M	$28.31M	$28.31M
YoY Change	30.17%	555.48%	555.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.257M	-$3.417M
YoY Change	-85.31%	-60.78%
Common Stock	$46.00K	$46.00K
YoY Change	4.55%	2.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.38M	$27.04M	$27.04M
YoY Change
Total Liabilities & Shareholders Equity	$55.49M	$55.35M	$55.35M
YoY Change	33.17%	115.3%	115.3%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$2.160M	$1.480M	$5.296M
YoY Change	1284.62%	212.9%	19.58%
Depreciation, Depletion And Amortization	$36.00K	$30.00K	$94.00K
YoY Change	89.47%	76.47%	42.42%
Cash From Operating Activities	$5.036M	$1.448M	$4.220M
YoY Change	2070.69%	-265.86%	2.18%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$46.00K	$106.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$16.96M	-$35.89M
YoY Change	-100.0%
Cash From Investing Activities	-$10.00K	-$17.01M	-$35.99M
YoY Change	-99.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$171.0K
YoY Change			-78.05%
Debt Paid & Issued, Net	$3.625M		$2.375M
YoY Change
Cash From Financing Activities	-$3.625M	9.046M	20.30M
YoY Change	-129.0%	-1261.23%	-2806.13%
NET CHANGE
Cash From Operating Activities	$5.036M	1.448M	4.220M
Cash From Investing Activities	-$10.00K	-17.01M	-35.99M
Cash From Financing Activities	-$3.625M	9.046M	20.30M
Net Change In Cash	$1.392M	-6.515M	-11.48M
YoY Change	-132.0%	294.37%	-439.56%
FREE CASH FLOW
Cash From Operating Activities	$5.036M	$1.448M	$4.220M
Capital Expenditures	$10.00K	$46.00K	$106.0K
Free Cash Flow	$5.026M	$1.402M	$4.114M
YoY Change	2066.38%		-0.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001374328
CY2023	dei	Entity Registrant Name EntityRegistrantName	FITLIFE BRANDS, INC.
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	50000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	107000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	113000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	71000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4598000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4507000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4507000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-52369
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3464383
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5214 S. 136th Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Omaha
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NE
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	68137
CY2023	dei	City Area Code CityAreaCode	402
CY2023	dei	Local Phone Number LocalPhoneNumber	991-5618
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	FTLF
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	32319000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4598241
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2023	dei	Auditor Name AuditorName	Weinberg & Company, P.A.
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash Cash	1139000	usd
CY2022Q4	us-gaap	Cash Cash	13277000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	759000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2046000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	705000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9091000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9105000	usd
CY2023Q4	ftlf	Sales Taxes Receivable SalesTaxesReceivable	1019000	usd
CY2022Q4	ftlf	Sales Taxes Receivable SalesTaxesReceivable	0	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	639000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	116000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	14693000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	23203000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	121000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	103000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26309000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	150000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	13294000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	358000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	792000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1847000	usd
CY2023Q4	us-gaap	Assets Assets	55346000	usd
CY2022Q4	us-gaap	Assets Assets	25707000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3261000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2995000	usd
CY2023Q4	ftlf	Accrued Expense And Other Liabilities Current AccruedExpenseAndOtherLiabilitiesCurrent	1026000	usd
CY2022Q4	ftlf	Accrued Expense And Other Liabilities Current AccruedExpenseAndOtherLiabilitiesCurrent	444000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	892000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	187000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	571000	usd
CY2022Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	590000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	87000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	54000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10337000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4270000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2413000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	28310000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4319000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	46000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	45000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30699000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30056000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3417000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8713000	usd
CY2023Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-292000	usd
CY2022Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27036000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21388000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55346000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25707000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	52700000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	28803000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31268000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16769000	usd
CY2023	us-gaap	Gross Profit GrossProfit	21432000	usd
CY2022	us-gaap	Gross Profit GrossProfit	12034000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12161000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6010000	usd
CY2023	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	1627000	usd
CY2022	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	257000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	94000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	66000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	13882000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6333000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	7550000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	5701000	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	289000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	121000	usd
CY2023	us-gaap	Interest Expense InterestExpense	1025000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	189000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-547000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	121000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7003000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5822000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1707000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1393000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	5296000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4429000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.18
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.97
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.89
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4490
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4553
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4905
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4975
CY2023	us-gaap	Net Income Loss NetIncomeLoss	5296000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4429000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-292000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5004000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4429000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21388000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	usd
CY2023	ftlf	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	165000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	473000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-292000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	5296000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	27036000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	17346000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	772000	usd
CY2022	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	7000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	363000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4429000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21388000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	5296000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4429000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-33000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-6000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	55000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	51000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	473000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	363000	usd
CY2023	ftlf	Amortization Of Deferred Finance Costs AmortizationOfDeferredFinanceCosts	15000	usd
CY2022	ftlf	Amortization Of Deferred Finance Costs AmortizationOfDeferredFinanceCosts	0	usd
CY2023	ftlf	Amortization Of Inventory Stepup AmortizationOfInventoryStepup	323000	usd
CY2022	ftlf	Amortization Of Inventory Stepup AmortizationOfInventoryStepup	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	882000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-247000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1026000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2636000	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-957000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1199000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	178000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-204000	usd
CY2023	ftlf	Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability	-83000	usd
CY2022	ftlf	Operating Lease Rightofuse Asset Net Of Amortization And Lease Liability OperatingLeaseRightofuseAssetNetOfAmortizationAndLeaseLiability	-55000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2679000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	115000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-356000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	184000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-77000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	122000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-44000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-42000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4220000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4130000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	106000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35993000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	171000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	779000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	22500000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2375000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20296000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-750000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11379000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3380000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13277000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9897000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1898000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13277000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	698000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	777000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">1.</em></b> <b>DESCRIPTION OF BUSINESS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FitLife Brands, Inc. (the “<i>Company</i>”) is a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “<i>NDS Products</i>”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the "<i>iSatori Products</i>"); and (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “<i>MRC Products</i>"); and (iv) MusclePharm.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“<i>GNC</i>”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online. The Company distributes the MRC Products primarily online. MusclePharm’s products are sold to both wholesale customers as well as online directly to the end consumer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“<i>Common Stock</i>”), trades under the symbol “FTLF” on the Nasdaq Capital Market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Developments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Acquisition of Mimi</i>’<i>s Rock Corp</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> December 4, 2022, </em>the Company entered into an Arrangement Agreement with Mimi’s Rock Corp. (“<i>MRC</i>”), pursuant to which the Company agreed to acquire MRC. On <em style="font: inherit;"> February 28, 2023, </em>the Company completed the acquisition of MRC. Total consideration for the acquisition of MRC was $17,099, of which $12,500 was funded using proceeds from a new term loan, and $4,599 from the Company’s available cash. See Note <em style="font: inherit;">8</em> to the financial statements for additional disclosure regarding the acquisition of MRC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Acquisition of MusclePharm Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> October 10, 2023, </em>the Company acquired substantially all of the assets of MusclePharm Corporation (“<i>MusclePharm</i>”) through an asset purchase transaction under Section <em style="font: inherit;">363</em> of the U.S. Bankruptcy Code. The Company acquired substantially all of the assets and assumed <em style="font: inherit;">none</em> of the liabilities of MusclePharm other than <i>de</i> <i>minimus</i> cure costs relating to certain assumed contracts. Total consideration for the acquisition was approximately $18,500 cash. Of this amount, $10,000 was funded using proceeds from a new term loan provided by First Citizens Bank, with the remainder funded from the Company’s available cash balances. See Note <em style="font: inherit;">9</em> for additional disclosure regarding the acquisition of MusclePharm.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Use of Estimates and Assumptions</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Customer and Vendor Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Total net sales to GNC during <em style="font: inherit;">2023</em> and <em style="font: inherit;">2022</em> were 33% and 67 % of total revenue for the years ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> respectively. Accounts receivable attributable to GNC as of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> represented 30% and 43% of the Company’s total accounts receivable balance, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">As of <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022,</em> there was <span style="-sec-ix-hidden:c109746644"><span style="-sec-ix-hidden:c109747028">one</span></span> vendor who accounted for 51% and 78% of the Company's consolidated accounts payable, respectively. For the year ended <em style="font: inherit;"> December 31, 2023, </em>there were <span style="-sec-ix-hidden:c109746647">three</span> vendors who accounted for 37%, 30%, and 10% of the Company's inventory-related purchases. For the year ended <em style="font: inherit;"> December 31, 2022, </em>there were <span style="-sec-ix-hidden:c109746651">two</span> vendors who accounted for 49% and 18% of the Company's inventory-related purchases, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	17000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	50000	usd
CY2023Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	571000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	590000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	107000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	4490
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	4553
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	415
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	422
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4905
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4975
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	26422000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	113000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26309000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	221000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	150000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8292000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8347000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	961000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	865000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	162000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	107000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9091000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9105000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	951000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	902000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	814000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	856000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	46000	usd
CY2023	us-gaap	Depreciation Depreciation	52000	usd
CY2022	us-gaap	Depreciation Depreciation	24000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15509000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4500000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4500000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4500000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4500000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2125000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	20125000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4598000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4507000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	160000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	468000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	380000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.44
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.65
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	7000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	35.88
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	379000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.09
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	117000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.1
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.7
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	30.31
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	484000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.82
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	484000
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y6M
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.82
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	359000
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	3.85
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5155000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	117000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.1
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	143000
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.15
CY2023	ftlf	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2022	ftlf	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	143480000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	165000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	143480000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1707000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1393000	usd
CY2023	ftlf	Effective Income Tax Rate Reconciliation Federal State And Foreign Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate	0.22	pure
CY2022	ftlf	Effective Income Tax Rate Reconciliation Federal State And Foreign Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationFederalStateAndForeignStatutoryIncomeTaxRate	0.24	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.223	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.24	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1562000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1397000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	28000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	128000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-86000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	75000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1707000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1393000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5097000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2034000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	25000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	-0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2540000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	-0	usd
CY2023Q4	ftlf	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns Bad Debt And Inventory DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsBadDebtAndInventory	490000	usd
CY2022Q4	ftlf	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns Bad Debt And Inventory DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsBadDebtAndInventory	157000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	193000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3023000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2384000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4644000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	537000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1621000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1847000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	20190000	usd
CY2023	us-gaap	Reclassifications Reclassifications	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE <em style="font: inherit;">13.</em> RECLASSIFICATIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Certain prior year amounts have been reclassified to conform to current presentation. These reclassifications had <em style="font: inherit;">no</em> effect on the reported operating income or net income on the Consolidated Statements of Income and Comprehensive Income. Certain costs previously classified as selling, general and administrative expense have been reclassified to merger and acquisition related expense on the Consolidated Statements of Income and Comprehensive Income.</p>

Files In Submission

Name	View Source	Status
0001437749-24-010119-index-headers.html	Edgar Link	pending
0001437749-24-010119-index.html	Edgar Link	pending
0001437749-24-010119.txt	Edgar Link	pending
0001437749-24-010119-xbrl.zip	Edgar Link	pending
ex_630109.htm	Edgar Link	pending
ex_630111.htm	Edgar Link	pending
ex_630112.htm	Edgar Link	pending
ex_630113.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ftlf-20231231.xsd	Edgar Link	pending
ftlf20231231_10k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
ftlf-20231231_cal.xml	Edgar Link	unprocessable
ftlf-20231231_def.xml	Edgar Link	unprocessable
ftlf-20231231_lab.xml	Edgar Link	unprocessable
ftlf-20231231_pre.xml	Edgar Link	unprocessable
ftlf20231231_10k_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FTLF
FITLIFE BRANDS, INC. Stock $ftlf

2024 Q1 Form 10-K Financial Statement

#000143774924010119 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FTLF FITLIFE BRANDS, INC. Stock $ftlf

2024 Q1 Form 10-K Financial Statement

#000143774924010119 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FTLF
FITLIFE BRANDS, INC. Stock $ftlf